The FDA has issued a regulation concerning the specific targets involved in the drug therapy, which includes Ras.
1 report, 1 independent
Updated Jun 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA has issued a regulation concerning the specific targets involved in the drug therapy, which includes Ras.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The FDA is involved in regulating drug approvals for GLP-1 Receptor Agonists.
- A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.
- A product, NitroMist®, requires FDA approval for sale, and distributor access is being established for federal supply channels.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- FDA approved Rasonque for metastatic PDAC, while Kras and Incyte also developed PDAC inhibitors and Incyte received a CMS settlement benefit.